Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Russia (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

United Arab Emirates (1)

Uzbekistan (1)

Explore our news

STADA ranks among top 10% of pharma firms on sustainability

STADA is making strong progress on achieving sustainability targets

Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe

Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrat…

STADA sets standard in Specialty

By launching the first medicine authorized in the EU for treating rare kidney disease

STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy

The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® 

STADA Health Report 2022: Europe experiencing worsening health conditions

Self-assessed burnout rates at all-time high; stress levels have increased;
more than one in three are struggling with sleep; appreciation f…

People with Parkinson’s are missing out on regular specialist advice in much of Europe

Many Parkinson’s patients across Europe are missing out on regular specialist advice on treating their condition, according to the findings …

STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab

Offers a comprehensive range of presentations to the EU adalimumab
biosimilars market

STADA brings in Berndt to further develop specialties and biosimilars offerings

Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars

Alvotech and STADA pave way to launching HUKYNDRA® (AVT02)

A citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie

STADA Health Report 2022

Europe, early summer 2021: Covid vaccination programmes across Europe were in full flow, bringing the prospect of returning to life more like we knew it before the pandemic. But had the virus changed the way we lived irreversibly? By asking detailed questions of 30,000 people across 15 countries, the STADA Health Report 2021 brought to light the immediate short-term effects of the pandemic on the lives of Europeans.

One year later, STADA checked in with Europeans to learn what longer-term effects the pandemic has left on Europe’s health landscape: How is their mental health holding up? What is worrying them? All the answers can be found in the STADA Health Report 2022

STADA on Social Media

Get in touch

For Journalists

STADA Arzrneimittel AG
Media Relations
61118 Bad Vilbel

For Customers, Business Partners & general inquiries

STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel